文献速递类风湿关节炎

他汀对类风湿关节炎冠状动脉粥样硬化进展及长期心血管风险的影响

The impact of statins on coronary atherosclerosis progression and long-term cardiovascular disease risk in rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该观察性队列纳入150例无心血管病的RA患者,用CT血管造影评估冠脉斑块,前瞻记录心血管事件,其中102例在6.9(0.3)年内复查斑块。他汀治疗总体未显著降低CVD风险,但基线CRP>0.5 mg/dl者风险降低,且他汀治疗>50%随访时间可改变炎症对新斑块形成的影响并预测非钙化斑块消退与钙化。

要点

  • 他汀总体未显著降低RA患者CVD风险,调整OR=0.39(95%CI 0.15,1.07),P=0.067。
  • 基线CRP>0.5 mg/dl者他汀与CVD风险降低相关,调整OR=0.09(95%CI 0.03,0.30),P<0.001。
  • 他汀治疗>50%随访时间预测非钙化斑块消退(OR=5.84)与钙化(OR=4.16)。

核心结论

  • 他汀治疗与高炎症RA患者长期心血管风险降低相关,并改变炎症对新冠脉斑块形成的影响,预测非钙化斑块消退与钙化。

研究设计与样本

  • 观察性队列研究纳入150例无CVD的RA患者,行CT血管造影评估冠脉斑块,前瞻记录心血管事件,102例在6.9(0.3)年内复查斑块。

主要发现

  • 时变他汀治疗总体未显著降低CVD风险,调整OR=0.39(95%CI 0.15,1.07),P=0.067。
  • 基线CRP>0.5 mg/dl者他汀与CVD风险降低相关,调整OR=0.09(95%CI 0.03,0.30),P<0.001;CRP<0.5 mg/dl者无此关联,P-interaction=0.023。
  • 他汀治疗>50%随访时间者CRP与新斑块形成无关,调整OR=0.42(95%CI 0.09,1.94);未用他汀者OR=1.89(95%CI 1.41,2.54),他汀治疗<50%时间者OR=1.41(95%CI 1.03,1.95),P-interaction=0.029。
  • 他汀治疗>50%随访时间预测非钙化病灶消退(调整OR=5.84,95%CI 1.29,26.55)和钙化(调整OR=4.16,95%CI 1.11,15.54),以及基线无斑块节段新发钙化斑块(调整OR=2.84,95%CI 1.09,7.41)。

临床怎么用

  • 对RA合并高炎症(CRP>0.5 mg/dl)者,他汀治疗可能降低长期心血管风险,并可能促进非钙化斑块稳定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate whether statins lower cardiovascular disease (CVD) risk in RA and if tentative benefits are related to changes in coronary plaque burden or composition. METHODS: In an observational cohort study, 150 patients without CVD underwent coronary atherosclerosis evaluation (total, noncalcified, partially and fully calcified plaque) with CT angiography. Prespecified cardiovascular events including cardiac death, myocardial infarction, unstable angina, revascularization, stroke, claudication and heart failure were prospectively recorded. Change in plaque burden and composition was re-assessed in 102 patients within 6.9 (0.3) years. RESULTS: Time-varying statin therapy, modeled using inverse probability treatment and censoring weights, did not significantly attenuate CVD risk in RA overall [adjusted odds ratio (OR) = 0.39 (95% CI: 0.15, 1.07), P =0.067]. However, statins associated with lower CVD risk in patients with baseline CRP > 0.5 mg/dl [adjusted OR = 0.09 (95%CI: 0.03, 0.30), P <0.001] but not in those with CRP < 0.5 mg/dl (P-interaction = 0.023), after controlling for Framingham-CVD score and time-varying bDMARD use. In patients treated with statin >50% of follow-up time, CRP did not associate with new plaque formation [adjusted OR = 0.42 (95% CI: 0.09, 1.94)], in contrast to statin-naïve [adjusted OR = 1.89 (95% CI:1.41, 2.54)] and statin-treated <50% time [adjusted-OR = 1.41 (95% CI: 1.03, 1.95), P-interaction = 0.029]. Statin therapy >50% follow-up time predicted dissipation [adjusted-OR = 5.84 (95% CI: 1.29, 26.55)] and calcification of prevalent noncalcified lesions [adjusted-OR = 4.16 (95% CI: 1.11, 15.54)], as well as new calcified plaque formation in segments without baseline plaque [adjusted-OR = 2.84 (95% CI:1.09, 7.41)]. CONCLUSION: Statin therapy associated with lower long-term cardiovascular risk in RA patients with higher inflammation. Moreover, statin therapy modified the impact of inflammation on new coronary plaque formation and predicted both regression and calcification of prevalent noncalcified lesions.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Karpouzas GA, Ormseth SR, Hernandez E, et al. The impact of statins on coronary atherosclerosis progression and long-term cardiovascular disease risk in rheumatoid arthritis. Rheumatology (Oxford). 2022. PMID: 34373923. doi:10.1093/rheumatology/keab642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。